Lincoln Pharmaceuticals Limited, originally established as a partnership in 1979, transitioned to a public limited company in 1995. The company specializes in manufacturing and trading pharmaceutical products, with facilities in Naroda and Khatraj, Gujarat. Initially relying on loan licensing until 1982, it now produces tablets, capsules, syrups, ointments, and small volume parenterals like injectables and eye drops. The Khatraj plant, a modern formulation facility, is crucial for expanding production capacity and includes a laboratory for in-house testing and R&D.
In 2018, Lincoln Pharmaceuticals introduced 'ProlinSpray,' a next-generation progesterone therapy. A significant structural change occurred in 2021-22 with the amalgamation of Lincoln Parenteral Limited, enhancing its operational capabilities. Further expansion included acquiring a plant in Mehsana for Cephalosporin products in 2022, demonstrating its commitment to growth and innovation in pharmaceuticals.
